The Experts below are selected from a list of 62391 Experts worldwide ranked by ideXlab platform
Carsten Tørholm - One of the best experts on this subject based on the ideXlab platform.
-
The Use of Dextran 70 as a Plasma Expander Increases the Intraoperative Bleeding in Total Hip Replacement
Clinical and Applied Thrombosis Hemostasis, 1997Co-Authors: P. Seest Jørgensen, Søren Wistisen Rasmussen, Carsten TørholmAbstract:In total hip replacement (THR) Dextran 70 is widely used as a plasma expander and as a thromboprophylactic agent. In a rec-hirudin multicenter dose-finding study approximately one third of the pati...
Carlos E. Sueldo - One of the best experts on this subject based on the ideXlab platform.
-
A comparison of TC7 and 32% Dextran 70 for prevention of postoperative adhesions in hamsters.
Obstetrics & Gynecology, 1991Co-Authors: C. L. Best, Rittenhouse D, Carlos E. SueldoAbstract:Prevention of postoperative adhesion formation has received considerable attention by infertility specialists. Barrier methods and hydroflotation solutions are currently used for adhesion prevention. The present study compared the efficacy of TC7 and 32% Dextran 70 in a hamster model. At laparotomy, 90 golden hamsters had a lesion created on the left uterine horn and repaired with absorbable suture. The first experiment used 3-0 chromic catgut suture in 43 hamsters; the second experiment used 5-0 polyglactin 910 suture in 47 hamsters. The animals were randomly divided into a control group (N = 25) which received no treatment, a TC7-treated group (N = 33), and a 32% Dextran 70-treated group (N = 32). The animals were sacrificed between 10-14 days after laparotomy and adhesions were graded (0 = no adhesions; 3 = severe adhesions). TC7 had average adhesion scores of 1.91 for chromic catgut and 2.25 for polyglactin 910; 32% Dextran 70 had average adhesion scores of 1.53 and 2.00, respectively. These scores were not different from the control average adhesion score of 1.80 for both chromic catgut and polyglactin 910. We conclude that TC7 and 32% Dextran 70 do not appear to be effective agents for preventing postoperative adhesions in this animal model.
-
a comparison of tc7 and 32 Dextran 70 for prevention of postoperative adhesions in hamsters
Obstetrics & Gynecology, 1991Co-Authors: C. L. Best, D Rittenhouse, Carlos E. SueldoAbstract:Prevention of postoperative adhesion formation has received considerable attention by infertility specialists. Barrier methods and hydroflotation solutions are currently used for adhesion prevention. The present study compared the efficacy of TC7 and 32% Dextran 70 in a hamster model. At laparotomy, 90 golden hamsters had a lesion created on the left uterine horn and repaired with absorbable suture. The first experiment used 3-0 chromic catgut suture in 43 hamsters; the second experiment used 5-0 polyglactin 910 suture in 47 hamsters. The animals were randomly divided into a control group (N = 25) which received no treatment, a TC7-treated group (N = 33), and a 32% Dextran 70-treated group (N = 32). The animals were sacrificed between 10-14 days after laparotomy and adhesions were graded (0 = no adhesions; 3 = severe adhesions). TC7 had average adhesion scores of 1.91 for chromic catgut and 2.25 for polyglactin 910; 32% Dextran 70 had average adhesion scores of 1.53 and 2.00, respectively. These scores were not different from the control average adhesion score of 1.80 for both chromic catgut and polyglactin 910. We conclude that TC7 and 32% Dextran 70 do not appear to be effective agents for preventing postoperative adhesions in this animal model.
P. Seest Jørgensen - One of the best experts on this subject based on the ideXlab platform.
-
The Use of Dextran 70 as a Plasma Expander Increases the Intraoperative Bleeding in Total Hip Replacement
Clinical and Applied Thrombosis Hemostasis, 1997Co-Authors: P. Seest Jørgensen, Søren Wistisen Rasmussen, Carsten TørholmAbstract:In total hip replacement (THR) Dextran 70 is widely used as a plasma expander and as a thromboprophylactic agent. In a rec-hirudin multicenter dose-finding study approximately one third of the pati...
C. L. Best - One of the best experts on this subject based on the ideXlab platform.
-
A comparison of TC7 and 32% Dextran 70 for prevention of postoperative adhesions in hamsters.
Obstetrics & Gynecology, 1991Co-Authors: C. L. Best, Rittenhouse D, Carlos E. SueldoAbstract:Prevention of postoperative adhesion formation has received considerable attention by infertility specialists. Barrier methods and hydroflotation solutions are currently used for adhesion prevention. The present study compared the efficacy of TC7 and 32% Dextran 70 in a hamster model. At laparotomy, 90 golden hamsters had a lesion created on the left uterine horn and repaired with absorbable suture. The first experiment used 3-0 chromic catgut suture in 43 hamsters; the second experiment used 5-0 polyglactin 910 suture in 47 hamsters. The animals were randomly divided into a control group (N = 25) which received no treatment, a TC7-treated group (N = 33), and a 32% Dextran 70-treated group (N = 32). The animals were sacrificed between 10-14 days after laparotomy and adhesions were graded (0 = no adhesions; 3 = severe adhesions). TC7 had average adhesion scores of 1.91 for chromic catgut and 2.25 for polyglactin 910; 32% Dextran 70 had average adhesion scores of 1.53 and 2.00, respectively. These scores were not different from the control average adhesion score of 1.80 for both chromic catgut and polyglactin 910. We conclude that TC7 and 32% Dextran 70 do not appear to be effective agents for preventing postoperative adhesions in this animal model.
-
a comparison of tc7 and 32 Dextran 70 for prevention of postoperative adhesions in hamsters
Obstetrics & Gynecology, 1991Co-Authors: C. L. Best, D Rittenhouse, Carlos E. SueldoAbstract:Prevention of postoperative adhesion formation has received considerable attention by infertility specialists. Barrier methods and hydroflotation solutions are currently used for adhesion prevention. The present study compared the efficacy of TC7 and 32% Dextran 70 in a hamster model. At laparotomy, 90 golden hamsters had a lesion created on the left uterine horn and repaired with absorbable suture. The first experiment used 3-0 chromic catgut suture in 43 hamsters; the second experiment used 5-0 polyglactin 910 suture in 47 hamsters. The animals were randomly divided into a control group (N = 25) which received no treatment, a TC7-treated group (N = 33), and a 32% Dextran 70-treated group (N = 32). The animals were sacrificed between 10-14 days after laparotomy and adhesions were graded (0 = no adhesions; 3 = severe adhesions). TC7 had average adhesion scores of 1.91 for chromic catgut and 2.25 for polyglactin 910; 32% Dextran 70 had average adhesion scores of 1.53 and 2.00, respectively. These scores were not different from the control average adhesion score of 1.80 for both chromic catgut and polyglactin 910. We conclude that TC7 and 32% Dextran 70 do not appear to be effective agents for preventing postoperative adhesions in this animal model.
J Lloyd - One of the best experts on this subject based on the ideXlab platform.
-
Prospective randomised open-label comparison of danaparoid with Dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
Thrombosis and haemostasis, 2001Co-Authors: Beng H. Chong, Alexander Gallus, John Cade, Harry N. Magnani, A Manoharan, M Oldmeadow, C. Arthur, K Rickard, J Gallo, J LloydAbstract:Aim: To compare clinical outcomes in a randomised comparison of treatment with danaparoid sodium (a heparinoid), or Dextran 70, for heparin-induced thrombocytopaenia (HIT) plus thrombosis. Methods: Forty-two patients with recent thrombosis and a clinical diagnosis of probable HIT who presented at ten Australian hospitals during a study period of six and one half years were randomly assigned to open-label treatment with intravenous danaparoid or Dextran 70, each combined with oral warfarin. Thirty-four patients (83%) had a positive platelet aggregation or 14C-serotonin release test for HIT antibody. Twenty-five received danaparoid as a bolus injection of 2400 anti-Xa units followed by 400 units per hour for 2 h, 300 units per hour for 2 h, and then 200 units per hour for five days. Seventeen received 1000 mL Dextran 70 on day one and then 500 mL on days 2-5. Patients were reviewed daily for clinical evidence of thrombus progression or resolution, fresh thrombosis or embolism, bleeding or other complications. The primary trial endpoint was the proportion of thromboembolic events with complete clinical resolution by the time of discharge from hospital. Results: With danaparoid, there was complete clinical recovery from 56% of thromboembolic events compared to 14% after Dextran 70 (Odds Ratio 10.53, 95% Confidence Interval 1.6-71.4; p = 0.02). Clinical recovery with danaparoid was complete or partial in 86% of thromboembolic events compared with 53% after Dextran 70 (Odds Ratio 4.55, 95% Confidence Interval 1.2-16.7; p = 0.03). Overall clinical effectiveness of danaparoid was rated as high or moderate in 88% of patients compared with 47% for Dextran 70 (p = 0.01). One patient given danaparoid died of thrombosis compared with three patients given Dextran 70. The platelet count returned to normal after a mean of 6.7 days with danaparoid and 7.3 days with Dextran 70. There was no major bleeding with either treatment. Conclusion: danaparoid plus warfarin treatment for HIT with thrombosis is effective, safe, and superior to Dextran 70 plus warfarin.